Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Thursday, September 12, 2019
Signant Health has been selected to provide electronic informed consent for a significant neuroscience study by the prestigious Shanghai Mental Health Center.
read more
Wednesday, January 29, 2020
Signant Health has announced new audit trail reviewing and reporting functionality today for its electronic clinical outcome assessment (eCOA) and remote sensor platform, TrialMax®.
read more
Wednesday, November 27, 2019
Signant Health announced has joined the non-profit Association of Clinical Research Organizations (ACRO).
read more
Signant Health has announced the appointment of Roger Smith as Chief Executive Officer.
read more
Tuesday, February 18, 2020
Signant Health has opened a new office facility in Blue Bell, Pennsylvania. Construction on the new office, which is the largest workplace in Signant Health’s global network, completed in February 2020.
read more
Signant Health will provide expert insights at the forthcoming DIA Global Annual Meeting in San Diego, CA June 23-27, 2019.
read more
Signature Biologics, LLC., announced their expanded operations footprint to include a new 36,000 sq ft facility in Irving, TX. This newly constructed space mirrors Signature Biologics' transparency in doing business with open floor plan and floor-to-...
read more
Friday, February 21, 2020
Sihuan announced Xuanzhu Biopharmaceutical acquired all interests and intellectual property rights of plazomicin.
read more
Wednesday, August 23, 2017
SillaJen has entered into a CRADA with the National Cancer Institute for the development of a combination therapy for colorectal cancer.
read more
Tuesday, January 23, 2018
Under the expanded agreement, ABL will provide development, manufacturing & QC release testing services for SillaJen's pipeline product, JX-970.
read more
Silo Pharma, Inc. has entered into an agreement with Frontage Laboratories, a CRO (contract research organization), providing integrated, science-driven, product development services throughout the drug discovery and development process that enable ...
read more
Wednesday, January 06, 2021
Silo Pharma has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma.
read more
Wednesday, August 07, 2024
Silo Pharma, Inc. announced that it has entered into an agreement with WuXi AppTec for a preclinical small animal study of SPU-16, a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS).
read more
Thursday, January 28, 2021
Silo Pharma has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease.
read more
Silo Pharma has engaged Veloxity Labs for bioanalysis supporting the ongoing investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic ...
read more